CONNECT BIOPHARMA HOLDINGS L

$1.40 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About CONNECT BIOPHARMA HOLDINGS L

Connect Biopharma Holdings Ltd is a holding company mainly engaged in the development of clinical-stage biopharmaceutical therapies for the treatment of T cell-driven inflammatory diseases. Its product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis (AD), and asthma. It is also developing CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1, (S1P1), for the treatment of inflammatory bowel disease (IBD). The Company mainly conducts its businesses in the China market.

Stock Analysis

last close $1.4
1-mo return 49.7%
3-mo return 110.6%
avg daily vol. 597.22T
52-week high 26.41
52-week low 0.56
market cap. $73M
forward pe -
annual div. -
roe -368%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 33.5%
baraka

Subscribe now for daily local and international financial news

Subscribe